Navigation Links
PharmAthene Presents New Data for Lyophilized rPA Anthrax Vaccine Showing Enhanced Immunogenicity

ANNAPOLIS, Md., July 15 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today announced results from a New Zealand White Rabbit study showing that its lyophilized recombinant Protective Antigen (rPA) anthrax vaccine was more immunogenic than a liquid formulation of rPA vaccine and produced a robust response with only 2 doses.  

The data were presented in a poster presentation entitled "Enhanced Immunogenicity in the New Zealand White Rabbit Model from a Lyophilized Anthrax Vaccine that is Reconstituted at Point-of-Use" at the 2010 International Conference on Emerging Infectious Diseases by Dr. Elizabeth Leffel, Director of Non-Clinical Sciences at PharmAthene.

Dr. Valerie Riddle, Senior Vice President and Medical Director for PharmAthene, commented, "Recently, the bipartisan Commission on the Prevention of Weapons of Mass Destruction Proliferation and Terrorism reiterated concerns that the United States is failing to address the threat posed to our citizens and military from a possible biological attack.  As we learned following the supply shortages last year of H1N1 vaccine, it is critically important that our government ensure we have adequate quantities of safe and effective medical countermeasures to deter or respond to a bioterror attack.  PharmAthene is committed to innovating and developing next generation anthrax vaccines and anti-toxins that offer improvements over earlier technologies, and we look forward to continued successful collaboration with our partners at the National Institutes of Health (NIH) and at the Office of the Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services, to advance these important medical countermeasures to protect Americans at home and on the battlefield."

Lyophilized rPA Findings Reported

The study, which was funded by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, was designed to assess if PharmAthene's lyophilized rPA vaccine reconstituted at point-of-use produced a more robust immune response than liquid rPA vaccine and whether the immune response from the lyophilized rPA changed over time following reconstitution.  

In the study, one group of New Zealand White rabbits (NZW) received liquid rPA (1.0 microgram dose) stored at 2-8 degrees Celsius via intramuscular injection on days 1 and 29.  The remaining four groups of NZW rabbits received lyophilized rPA (1.0 microgram dose) stored at 2-8 degrees Celsius, reconstituted and administered via intramuscular injection on days 1 and 29.  Blood samples were collected pre-dose and on days 15, 29 and 43 for measurement by toxin neutralization assay (TNA) and enzyme linked immunosorbent assay (ELISA) for the presence of IgG anti-PA antibodies.  

Results demonstrated that lyophilized rPA vaccine, reconstituted at less than 2 hours prior to use, was more immunogenic than the liquid rPA vaccine when measured by both TNA and ELISA (p<0.05).  The study investigators concluded that lyophilized rPA reconstituted at point-of-use was more immunogenic than liquid rPA and produced a robust immune response after only 2 doses.  

"We're very encouraged by this preliminary study," continued Dr. Riddle.  "The initial non-clinical animal data suggest that a lyophilized rPA vaccine formulation may be able to provide protection against anthrax infection with fewer doses than a liquid vaccine formulation.  We will be conducting additional studies to confirm these preliminary results.  In addition, a lyophilized formulation could yield important practical advantages in the field."

Previously, the Company announced that its lyophilized rPA vaccine candidate was structurally stable and potent at various temperatures up to and including 70 degrees Celsius.  One of the goals of PharmAthene's rPA program is to develop a stable cold-chain-free vaccine, which could be stored and distributed at room temperature -- an important advantage for deployment in the civilian Strategic National Stockpile.

The Institute of Medicine has declared an urgent need to develop and stockpile next generation anthrax vaccines employing modern vaccine technology, which offer the potential for improved safety, convenience, cost-effectiveness, and more rapid immunity.   PharmAthene is committed to working with its partners in the United States government to address this need.

Funding for the lyophilized rPA vaccine program was provided under a Challenge grant (UC1 AI067223) from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.  

About Anthrax

According to the Centers for Disease Control and Prevention, anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in hoofed mammals and can also infect humans. Symptoms of disease vary depending on how the disease is contracted, but usually occur within seven days after exposure. The serious forms of human anthrax are inhalation anthrax, cutaneous anthrax, and gastrointestinal anthrax. Initial symptoms of inhalation anthrax infection may resemble a common cold. After several days, the symptoms may progress to severe breathing problems and shock. Inhalation anthrax is often fatal, even if treated by antibiotics.  Currently, antibiotics are the only drugs available for therapeutic or prophylactic use for inhalation anthrax, and post-exposure prophylaxis is the only FDA-approved indication for such products.  However, antibiotic therapy, while useful, is believed to be associated with a number of limitations, including: (1) lack of activity against the toxins produced by the B. anthracis bacteria, (2) need for long-term dosing to achieve full protection, complicated by side effects and non-compliance, (3) lack of efficacy when administered late in the anthrax disease cycle, and (4) lack of effectiveness against multi-drug resistant or genetically engineered strains of anthrax.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax™ -- a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim®-- a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia® -- a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents

For more information about PharmAthene, please visit

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements.  Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements.  PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements.  Risks and uncertainties include risks associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, and/or process validation of manufacturing processes for our product candidates, unexpected  determinations that these product candidates prove not to be effective and/or capable of being marketed as products  as well as risks detailed from time to time in PharmAthene's Form 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC").  In particular, significant additional non-clinical animal studies, human clinical trials, and manufacturing development work remain to be completed for our lyophilized rPA anthrax vaccine candidate. At this point there can be no assurance that this product candidate will be shown to be safe and effective and approved by regulatory authorities for use in humans.  Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PharmAthene Develops Thermostable Lyophilized rPA Anthrax Vaccine Under a Challenge Grant From the National Institutes of Health
2. PharmAthene Presents rPA Anthrax Vaccine Data at the 2009 HHS PHEMCE Stakeholders Workshop
3. PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop
4. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
5. PharmAthene Submits SparVax(TM) Regulatory Strategy to FDA
6. PharmAthene to Host a Conference Call and Webcast on Wednesday, April 29th at 4:30 PM to Provide an Update on the SparVax(TM) rPA Anthrax Vaccine Program
7. PharmAthene Initiates Phase I Clinical Trial of Nerve Agent Bioscavenger Protexia(R)
8. PharmAthene Presents Data for Protexia(R) and Valortim(R) at 2008 BARDA Industry Conference / PHEMCE Stakeholders Workshop
9. PharmAthenes Recombinant Butyrylcholinesterase (rBChE) May Play A Neuroprotective Role in Alzheimers Disease
10. PharmAthene to Webcast its Third Quarter Conference Call on November 13, 2007 at 4:30 P.M. Eastern Time
11. Tolerx Presents Baseline Data from DEFEND-1 Study Validating C-Peptide as Critical Clinical Measure for New-Onset Type 1 Diabetes
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the Global Cell Surface Testing Market: ... report to their offering.  --> ... addition of the  "2016 Future Horizons ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... the "Advanced Wound Care Market by Type (Dressings, ... End User (In-Patient Facility, Out-Patient Facility), and Geography - ... --> --> ... description, definition and forecast of the global advanced wound ...
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... DE (PRWEB) , ... November 27, 2015 , ... ... member of the well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s ... an independent group of Microsoft Dynamics SL software users, partners, industry experts and ...
(Date:11/27/2015)... MINNEAPOLIS, Minn. (PRWEB) , ... November 27, 2015 ... ... you start failing. Secura Consultants has prided itself for not only fulfilling the ... best income protection solutions at an affordable price and providing top-tier customer service. ...
(Date:11/27/2015)... ... ... CBD College is proud to announce that on November 20th, ... its Diagnostic Medical Sonography program. CBD College is honored to join this very short ... universities in the state of California make the cut. CBD College is officially the ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap ... and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph Health System’s ... STEMI and Sepsis conditions present in similar ways and require time-critical intervention to avoid ...
Breaking Medicine News(10 mins):